Jing Marantz Sells 5,798 Shares of Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Jing Marantz sold 5,798 shares of the stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $44.48, for a total value of $257,895.04. Following the sale, the insider owned 95,687 shares of the company’s stock, valued at approximately $4,256,157.76. The trade was a 5.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Scholar Rock Stock Performance

Shares of NASDAQ SRRK opened at $47.82 on Friday. Scholar Rock Holding Corporation has a 12 month low of $22.71 and a 12 month high of $48.28. The company has a market cap of $4.88 billion, a P/E ratio of -15.18 and a beta of 0.63. The business’s 50 day moving average is $43.59 and its two-hundred day moving average is $37.24. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.41.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same period last year, the business posted ($0.66) EPS. On average, equities analysts expect that Scholar Rock Holding Corporation will post -2.42 EPS for the current year.

Hedge Funds Weigh In On Scholar Rock

Hedge funds and other institutional investors have recently modified their holdings of the stock. Ramirez Asset Management Inc. bought a new stake in Scholar Rock in the third quarter valued at $37,000. Penserra Capital Management LLC bought a new position in shares of Scholar Rock during the third quarter valued at $56,000. Bessemer Group Inc. boosted its stake in shares of Scholar Rock by 970.0% in the 3rd quarter. Bessemer Group Inc. now owns 2,322 shares of the company’s stock valued at $86,000 after purchasing an additional 2,105 shares in the last quarter. Strs Ohio bought a new stake in shares of Scholar Rock in the 1st quarter worth about $77,000. Finally, Elevation Point Wealth Partners LLC acquired a new stake in shares of Scholar Rock during the 2nd quarter worth about $94,000. Institutional investors own 91.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on SRRK. Barclays increased their target price on shares of Scholar Rock from $45.00 to $52.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. UBS Group initiated coverage on Scholar Rock in a research note on Wednesday, January 7th. They issued a “buy” rating and a $60.00 target price for the company. Bank of America assumed coverage on Scholar Rock in a research report on Thursday, October 9th. They issued a “buy” rating and a $53.00 target price for the company. Truist Financial lowered their price target on shares of Scholar Rock from $54.00 to $44.00 and set a “buy” rating on the stock in a report on Monday, October 20th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. Four investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $50.14.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).